Stero Biotechs News
14 articles
growth-positive
Stero Biotechs supports an Exploratory Study of CBD-based treatment for COVID-19 severe patients
Stero Biotechs is supplying and supporting a clinical trial for Cannabidiol Treatment of Severe and Critical COVID-19 Pulmonary Infection at Rabin Medical Center. The study aims to benefit COVID-19 patients in severe states with respiratory failure. Stero plans to expand the study pending the success of the Proof of Concept phase. Stero Biotechs is a clinical-stage company focused on CBD formulation research and development. They have a strong partnership with MOR Research Applications, the TTO of CLALIT HEALTH SERVICES.
PartnersCustomers
Neutral
https://www.israel-cannabis.com/press-release/stero-biotechs-announces-first-patient-in-phase-2a-clinical-trial-for-cbd-effects-on-chronic-spontaneous-urticaria/
The article is about iCAN, an Israeli company that is globally recognized in the medical cannabis industry. The company is focused on developing novel cannabis formulations and devices. iCAN Services provides business and scientific services for cannabis companies in all stages of development. The company also has a joint venture with Steep Hill, a global leader in cannabis testing and genomics, to build a world-class advanced testing facility and set the global standard in cannabis testing.
Partners
growth-positive
CBD may improve steroid therapy in autoimmune, Covid-19 patients
Israeli canna-tech startup Stero Therapeutics was set to launch a clinical trial with 10 Covid-19 patients at Rabin Medical Center in Petah Tikva when the hospital ran out of patients due to the decrease in new Covid-19 cases. Stero is now turning its attention toward Europe, where there is still no shortage of people suffering from the virus. Stero aims to determine if CBD, the non-psychoactive component in cannabis, can enhance the effect of corticosteroids or enable reducing steroid dosage while maintaining or improving its therapeutic effects.
InvestmentExpand
growth-positive
Israeli Biotech Company Starts Clinical Trials of CBD-Steroid Treatment for Virus
Israel-based biotech company Stero Biotechs has started a small-scale clinical trial on the effects of a steroid-Cannabidiol (CBD) treatment on hospitalized COVID-19 patients. The company plans to expand the trial pending its success and aims to enhance the current treatment for life-threatening conditions. Stero Biotechs focuses on the research and development of novel CBD-based treatment solutions.
CustomersPartners
growth-positive
Stero Biotechs Announce an IP Protected Clinical Trial for COVID-19 Patients Using a CBD-Steroid Treatment
Stero Biotechs, in collaboration with its partner Mor Research Applications, announced a new clinical trial to treat hospitalized patients with COVID-19 using CBD. The small-scale trial will treat 10 patients initially, with plans to expand to a larger trial if successful. Stero Biotechs has a wide patent covering over 130 autoimmune and inflammatory diseases, allowing for the use of CBD in various forms and dosages. The company aims to enhance the therapeutic effect of steroid treatment for COVID-19 patients. The trial will evaluate the safety and efficacy of the CBD treatment. Stero Biotechs is a clinical-stage company focused on CBD-based treatment solutions.
Customers
growth-negative
Kalytera and Stero Biotechs Will Not Proceed with Acquisition
Kalytera Therapeutics Inc. has announced that it will not proceed with the previously announced acquisition of Stero Biotechs, Ltd. The termination of the acquisition is a growth-negative impact on the company. Kalytera is now in active discussions with other companies to expand and diversify its operations. The key theme of the article is the termination of the acquisition. The structured issue is the acquisition. The article does not mention any investors, customers, or partners. The date of the event described in the article is April 13, 2020. My confidence in the answer is 8/10.
Acquisition
growth-positive
Kalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. Acquisition
Kalytera Therapeutics Inc. has provided additional details about its planned acquisition of Stero Biotechs. Stero is a privately held Israeli company developing cannabidiol (CBD) for co-administration with steroids. The acquisition price is $30 million, with $15 million to be paid in Kalytera common shares at closing. Stero has ongoing Phase 2a clinical studies evaluating CBD in steroid sparing, and earlier clinical studies have shown that co-administration of CBD with steroids may significantly reduce the need for steroid treatment. The acquisition is subject to certain conditions and regulatory approvals. At closing, Stero shareholders will receive an initial payment of $15 million in Kalytera shares, which will be approximately 37.5% of Kalyteras outstanding shares.
Acquisition
growth-positive
Kalytera Announces Extension of Maturity Date of Promissory Note
Kalytera Therapeutics has announced its intention to acquire Stero Biotechs, a privately held Israeli company developing cannabidiol (CBD) for co-administration with steroids. The acquisition is expected to position Kalytera as a leader in CBD pharmaceutical development. Steros ongoing Phase 2a clinical studies have shown that co-administration of CBD with steroids can significantly reduce the need for steroid treatment. Kalytera plans to engage Canadian and Israeli investment banks and advisers to manage a private placement financing of at least USD $10 million, with USD $6 million allocated to advance their GVHD program. The company will also extend the maturity date of a secured promissory note in favor of the former shareholders of Talent Biotechs Ltd., a subsidiary of Kalytera, to May 15, 2020.
AcquisitionInvestment
growth-positive
Kalytera to Acquire Stero Biotechs, Ltd.
Kalytera Therapeutics, Inc. has signed a Letter of Intent to acquire Stero Biotechs, Ltd., a privately held Israeli company that is developing cannabidiol (CBD) for co-administration with steroids. The acquisition will bring Kalytera multiple additional CBD pharmaceutical programs and will address large commercial opportunities in steroid sparing. The transaction is expected to close on or about May 1, 2020, and is subject to shareholder approval and other conditions. Upon close of the acquisition, Mr. David Bassa, Chairman and CEO of Stero, will be appointed as Chairman and CEO of Kalytera.
AcquisitionManagement Changes
Are steroids truly a necessary evil? - a groundbreaking CBD-based alternative
growth-positive
Clinical Trial in Israel Will Evaluate Cannabidiol-based Product...
Stero Biotechs, an Israel-based company, is set to conduct a clinical trial to test a CBD-based solution as a potential treatment for steroid-dependent Crohns disease. The trial aims to evaluate the safety, tolerability, and efficacy of Steros ST-SDCD-01, a steroid-sparing treatment. The randomized, double-blind, placebo-controlled Phase 2a trial will involve 30 people with steroid-dependent Crohns disease and will be conducted at four Israeli medical facilities. Stero Biotechs owns a patent for the use of CBD as a steroid-sparing treatment in over 130 inflammatory and autoimmune diseases.
Customers
growth-positive
Stero Biotechs to Commence Phase 2a Clinical Trial of Cannabidiol-Based Formulation for Patients With Crohn's Disease
Stero Biotechs has received approval to move forward with a second Phase 2a clinical trial for its CBD-based solution in an effort to lower steroid dosage in patients with Steroid Dependent Crohns Disease (SDCD). The trial aims to evaluate the tolerability, safety, and efficacy of the formulation as a steroid-sparing therapy. The study will be conducted over 12 months across four Israeli medical facilities. Stero Biotechs is a clinical-stage company focused on CBD formulation research and development.
Customers
growth-positive
Stero Biotechs begins trial of CBD to reduce steroid use in autoimmune hepatitis
Stero Biotechs has received Ethics Committee approval to begin a clinical trial of cannabidiol (CBD) formulation for patients with liver disease. The company plans to enroll 15 patients with autoimmune hepatitis in the phase 2 trial. The goal is to reduce the dose and duration of steroid therapy. The company believes that CBD can help lower steroid prescription doses and improve the therapeutic effect for patients who are resistant to steroids. Stero Biotechs intends to continue researching indications for the proprietary formulation in 2019.
Customers
growth-positive
STERO Biotechs Secures Patent of CBD as Steroid Sparing Treatment, Breakthrough Will Potentially Allow Significant Dosage Reduction
STERO Biotechs Ltd. has received a notice of allowance for a U.S. patent on a steroid sparing Cannabidiol (CBD)-based treatment for autoimmune and chronic inflammatory diseases. The treatment aims to minimize the adverse effects of steroids while retaining their therapeutic effect. Clinical trials are set to begin in Q4 2018. The company has also established a partnership with MOR Research Applications, the tech transfer company of CLALIT HEALTH SERVICES, to reach a larger patient base. STERO Biotechs is committed to developing novel CBD-based treatment solutions that reduce the need for steroid therapy.
InvestmentPartners
